VolitionRx Limited (NYSE American: VNRX) announced a technical milestone in the detection of nucleosomes from capillary blood samples in critically ill patients with sepsis using a lateral flow finger-prick prototype. The study, conducted as part of the SUMMIT program, demonstrated the feasibility of detecting nucleosomes in capillary samples, supporting the potential for early detection of immune disruptions associated with conditions like sepsis across point-of-care and non-laboratory settings.
The company noted that this prototype builds on prior results showing correlation between venous blood samples tested with its lateral flow system and its established Nu.Q nucleosome assay. By enabling testing from a finger-prick sample, Volition aims to expand access to testing through point-of-care use and broaden its addressable market. This approach could support future commercialization efforts, including potential partnerships to increase access in regions with limited laboratory infrastructure.
The ability to detect nucleosomes—a marker of cell death and NETosis—from a simple finger-prick could significantly impact sepsis management, where early detection is critical. Sepsis is a life-threatening condition that arises when the body’s response to infection causes widespread inflammation. Current diagnostic methods often require venous blood draws and laboratory analysis, which can delay treatment.
Volition’s achievement aligns with the growing trend toward decentralized testing, bringing diagnostics closer to patients. The company has been developing simple, cost-effective blood tests for early detection and monitoring of diseases, including certain cancers and sepsis. The finger-prick prototype represents a step forward in making these tests more accessible, particularly in underserved areas where laboratory infrastructure is lacking.
For more details on the announcement, the full press release is available at https://ibn.fm/ioEmu.
Volition is a multinational epigenetics company focused on advancing the science of epigenetics to save lives and improve outcomes for people and animals with life-altering diseases. Through its subsidiaries, the company develops and commercializes simple, easy-to-use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Volition’s research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London. More information is available at the company’s website: www.Volition.com.
